174 related articles for article (PubMed ID: 38305916)
1. Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression.
Pimenta R; Malulf FC; Romão P; Caetano GVB; da Silva KS; Ghazarian V; Dos Santos GA; Guimarães V; Silva IA; de Camargo JA; Recuero S; Melão BVLA; Antunes AA; Srougi M; Nahas W; Leite KRM; Reis ST
J Cancer Res Clin Oncol; 2024 Feb; 150(2):70. PubMed ID: 38305916
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S
Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908
[TBL] [Abstract][Full Text] [Related]
3. [TMPRSS2-Erg/AR-V7: Prognostic value of tests in urine and biopsy rince material in prostate cancer].
Plante G; Bories PN; Denjean L; Pigat N; Sibony M; Goffin V; Barry Delongchamps N
Prog Urol; 2020 Mar; 30(3):162-171. PubMed ID: 32127312
[TBL] [Abstract][Full Text] [Related]
4. Tissue Expression of Androgen Receptor Splice Variant 7 at Radical Prostatectomy Predicts Risk of Progression in Untreated Nonmetastatic Prostate Cancer.
Sciarra A; Maggi M; Salciccia S; Nicolai A; Tortorella E; Giantulli S; Magliocca FM; Silvestri I; Taglieri L; Cattarino S; Scarpa S
Oncology; 2021; 99(4):251-255. PubMed ID: 33461196
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.
Hillebrand AC; Pizzolato LS; Neto BS; Branchini G; Brum IS
PLoS One; 2018; 13(7):e0200613. PubMed ID: 30028845
[TBL] [Abstract][Full Text] [Related]
6. Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression.
Zhao H; Coram MA; Nolley R; Reese SW; Young SR; Peehl DM
J Urol; 2012 Dec; 188(6):2158-64. PubMed ID: 23088973
[TBL] [Abstract][Full Text] [Related]
7. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES
Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829
[TBL] [Abstract][Full Text] [Related]
8. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
9. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of potential regulatory signaling molecules correlate with androgen receptor splice variants AR-V7 and AR-V567es in prostate cancer metastasis.
Kiliccioglu I; Bilen CY; Sozen S; Konac E
Gene; 2021 Mar; 772():145377. PubMed ID: 33359129
[TBL] [Abstract][Full Text] [Related]
11. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
12. Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients.
Li H; Wang Z; Xiao W; Yan L; Guan W; Hu Z; Wu L; Huang Q; Wang J; Xu H; Zhang X; Ye Z
Mod Pathol; 2018 Jan; 31(1):198-208. PubMed ID: 29076496
[TBL] [Abstract][Full Text] [Related]
13. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
Zhu Y; Sharp A; Anderson CM; Silberstein JL; Taylor M; Lu C; Zhao P; De Marzo AM; Antonarakis ES; Wang M; Wu X; Luo Y; Su N; Nava Rodrigues D; Figueiredo I; Welti J; Park E; Ma XJ; Coleman I; Morrissey C; Plymate SR; Nelson PS; de Bono JS; Luo J
Eur Urol; 2018 May; 73(5):727-735. PubMed ID: 28866255
[TBL] [Abstract][Full Text] [Related]
14. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT
Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
16. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
18. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
19. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R
JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]